Merck discontinues clinical development programs for vibostolimab, favezelimab Ruchika Sharma18 Dec 2024 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for...
Merck discontinues Phase 3 trial for lung cancer combo drug Ruchika Sharma11 Aug 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the Phase 3 KeyVibe-008 trial based on...
Merck discontinues Vibostolimab, Pembrolizumab coformulation arm of Phase 3 KeyVibe-010 trial in Melanoma Ruchika Sharma14 May 2024 4:17 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the vibostolimab and pembrolizumab...
Merck announces positive results from phase 2 trial evaluating coformulation of vibostolimab, pembrolizumab in lung cancer patients Ruchika Sharma10 Dec 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced full results from the non-registrational Phase 2 KeyVibe-002...
